Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5042688 | 0.99 | CHRM4 (0.44) | CHRM4NCF1GRM2FFAR4KMT2A | |
| SCHEMBL5036061 | 0.80 | NCF1 (0.54) | CHRM4NCF1GRM2 | |
| SCHEMBL5035794 | 0.79 | NCF1 (0.52) | CHRM4NCF1KMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5033349 | 0.78 | NCF1 (0.51) | CHRM4NCF1KMT2AMEN1ALDH1A1 | |
| SCHEMBL5033277 | 0.78 | TSHR (0.46) | NCF1ALDH1A1 | |
| SCHEMBL5036138 | 0.77 | NMT1 (0.47) | CHRM4NCF1KMT2A | |
| SCHEMBL5033312 | 0.77 | NCF1 (0.45) | CHRM4NCF1KMT2A | |
| SCHEMBL5040453 | 0.77 | NCF1 (0.45) | NCF1ALDH1A1 | |
| SCHEMBL5133453 | 0.76 | HTR6 (0.47) | CHRM4NCF1ALDH1A1 | |
| SCHEMBL5042845 | 0.76 | NCF1 (0.39) | CHRM4NCF1GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CHRM4 2051/4885NCF1 1052/4885GRM2 2012/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CHRM4 2051/4885NCF1 1052/4885GRM2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.